Cannabinoid receptor 2 deficiency exacerbates inflammation and neutrophil recruitment by Kapellos, Theodore S et al.
 
 
University of Birmingham
Cannabinoid receptor 2 deficiency exacerbates
inflammation and neutrophil recruitment
Kapellos, Theodore S; Taylor, Lewis; Feuerborn, Alexander ; Valaris, Sophia; Hussain,
Mohammed T; Rainger, George; Greaves, David R; Iqbal, Asif Jilani
DOI:
10.1096/fj.201802524R
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Kapellos, TS, Taylor, L, Feuerborn, A, Valaris, S, Hussain, MT, Rainger, G, Greaves, DR & Iqbal, AJ 2019,
'Cannabinoid receptor 2 deficiency exacerbates inflammation and neutrophil recruitment', FASEB Journal, vol.
33, no. 5. https://doi.org/10.1096/fj.201802524R
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
THE
JOURNAL • RESEARCH • www.fasebj.org
Cannabinoid receptor 2 deficiency exacerbates
inflammation and neutrophil recruitment
Theodore S. Kapellos,*,1 Lewis Taylor,*,1 Alexander Feuerborn,* Sophia Valaris,* Mohammed T. Hussain,†
G. E. Rainger,† David R. Greaves,*,2,3 and Asif J. Iqbal†,2,4
*Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom; and †Institute of Cardiovascular Sciences, College of
Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
ABSTRACT:Cannabinoidreceptor (CB)2 isanimmunecell–localizedGPCRthathasbeenhypothesizedto regulate the
magnitude of inflammatory responses.However, there is currently no consensus as to themechanismbywhichCB2
mediates its anti-inflammatory effects in vivo. To address this question, we employed a murine dorsal air pouch
model with wild-type and CB2
2/2 8–12-wk-old female and male C57BL/6 mice and found that acute neutrophil
and lymphocyte antigen 6 complex, locus Chi monocyte recruitment in response to Zymosan was significantly
enhanced in CB2
2/2 mice. Additionally, levels of matrix metalloproteinase 9 and the chemokines C-C motif che-
mokine ligand (CCL)2, CCL4, and C-X-C motif chemokine ligand 10 in CB2
2/2 pouch exudates were elevated at
earlier time points. Importantly, using mixed bone marrow chimeras, we revealed that the proinflammatory phe-
notype inCB2
2/2mice is neutrophil-intrinsic rather than stromal cell–dependent. Indeed, neutrophils isolated from
CB2
2/2 mice exhibited an enhanced migration-related transcriptional profile and increased adhesive phenotype,
and treatment of human neutrophils with a CB2 agonist blocked their endothelial transmigration. Overall, we have
demonstrated that CB2 plays a nonredundant role during acute neutrophil mobilization to sites of inflammation
and, as such, it could represent a therapeutic target for the development of novel anti-inflammatory compounds to
treat inflammatory human diseases.—Kapellos, T. S., Taylor, L., Feuerborn, A., Valaris, S., Hussain,M. T., Rainger,
G. E., Greaves, D. R., Iqbal, A. J. Cannabinoid receptor 2 deficiency exacerbates inflammation and neutrophil
recruitment. FASEB J. 33, 6154–6167 (2019). www.fasebj.org
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Since the discovery of cannabinoid receptor (CB) 1, CB2,
and their endogenous lipid ligands (known as the endo-
cannabinoids), almost 3 decades of work has now estab-
lished that these 2 GPCRs and their cognate ligands,
alongside the enzymes that synthesize and degrade these
endogenous lipids, make up the endocannabinoid system
(1–4).
Both CB1 and CB2 are class A rhodopsin-like GPCRs
and areGi/o-coupled; therefore, their ligation results in the
inhibition of adenylyl cyclase and the lowering of in-
tracellular cAMP levels (5). However, signaling via the
G-protein bg subunits can also lead to intracellular Ca2+
release, activation of ion channels, b-arrestin recruitment,
and PI3K and mitogen-activated protein signaling (6, 7).
ABBREVIATIONS: 2-AG, 2-arachidonoylglycerol; BSA, bovine serum albumin; C5a, complement component 5a; CB, cannabinoid receptor; CCL, C-C
motif chemokine ligand; Ccr7, C-C chemokine receptor type 7; Clec7a, C-type lectin domain containing 7A; Cnr2, cannabinoid receptor 2; CXCL, C-X-C
motif chemokine ligand; FACS, fluorescence-activated cell sorting; FCS, fetal calf serum; fMLP, N-formylmethionyl-leucyl-phenylalanine; HDBEC,
human dermal blood endothelial cell; ICAM, intercellular adhesion molecule; JWH133, (6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-
trimethyl-6H-dibenzo[b,d]pyran; Ly-6C, lymphocyte antigen 6 complex, locus C; Ly-6G, lymphocyte antigen 6 complex, locus G; Ly-6Chi, high Ly-6C;
Ly-6Clo, low Ly-6C; MMP-9, matrix metalloproteinase 9; PMN, polymorphonuclear neutrophil; qPCR, quantitative PCR; SR144528, 5-(4-chloro-3-
methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide; Vim, vimentin; WT, wild type
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CB1 and CB2 exhibit distinct expression patterns, with
CB1 highly enriched throughout the CNS (8) and CB2
predominantly expressed in leukocytes, such as B cells,
NK cells, mast cells, neutrophils, monocytes, and T cells
(6). However, recent data have demonstrated that CB2
expression can also be found in the brain (9). The presence
of CB2 on immune cells has resulted in focused academic
interest surrounding the role CB2 plays in inflammation
and inflammatory disease, and indeed, CB2 ligation has
been demonstrated to regulate various aspects of immune
cell function [reviewed in Turcotte et al. (10)]. For instance,
it was shown that CB2 promotes the retention of B cells in
themurine spleen (11) and it plays an important role in the
control of acute inflammatory responses (12, 13).
However, and despite the fact that CB2 activation has
been found to have a positive outcome in a range of acute
and chronic inflammatoryanimalmodels ofdiseases, such
as inflammatory bowel disease (14, 15), sepsis (16, 17),
multiple sclerosis (18, 19), ischemia reperfusion injury
(20–23), and atherosclerosis (24, 25), the exact mechanism
underpinning these beneficial effects remains unknown.
One hypothesis put forward is that activation of CB2
blocks immune cell chemotaxis; however, we recently
found that CB2 does not play a role in regulating primary
macrophage chemotaxis (26). Additionally,most previous
studies investigating CB2 within inflammation have used
indirect or semiquantitative measures of immune cell re-
cruitment and only examine a single time point.
To overcome these limitations, we conducted a fully
quantitative analysis of the effect of global genetic deletion
of CB2 on neutrophil, and other innate immune cell, re-
cruitment in a model of self-resolving acute inflammation
at multiple time points. We report that CB2 suppresses
neutrophil recruitment to the dorsal air pouch via a
neutrophil-intrinsic mechanism. Neutrophils of CB2-de-
ficient animals have a dysregulated transcriptomic profile
consistentwith a promigratory phenotype that ismanifest
in increased adherence of murine CB2
2/2 neutrophils to
intercellular adhesion molecule (ICAM)1 in vitro and de-
creased adhesion and transmigration of CB2 agonist–
treated human neutrophils to activated endothelial cells.
MATERIALS AND METHODS
Reagents
Bio-gel polyacrylamide beads (P-100 fine, 45–90 mm) were pur-
chased from Bio-Rad (Hercules, CA, USA); anti-mouse CD45.1
(A20),CD45.2 (104),CD11b(M1/70),CD115(AFS98), lymphocyte
antigen 6 complex, locus C (Ly-6C) (HK1.4), and lymphocyte
antigen 6 complex, locus G (Ly-6G) (1A8) were purchased from
BioLegend (SanDiego, CA, USA); anti-mouse CD45 (30-F11) was
obtained from BD Biosciences (San Jose, CA, USA); quantitative
PCR (qPCR)primerswerepurchased fromQiagen (Germantown,
MD, USA); and all cell culture media and reagents were obtained
from GE Healthcare (Waukesha, WI, USA).
Animals
Animalstudieswereperformedwith localethicalapproval fromthe
Dunn School of Pathology Animal Welfare Ethical Review Board
and according to the United Kingdom Home Office regulations
(Guidance on the Operation of Animals, Scientific Procedures Act,
1986). C57BL/6 and B6.SJL mice were obtained directly from the
Biomedical Sciences Unit (Oxford, United Kingdom) and were
housed ina12-h light/darkcyclewith freeaccess to foodandwater.
B6.129P2-Cnr2tm1Dgen/J mice (herein referred to as CB2
2/2 mice)
were purchased from theThe JacksonLaboratory (BarHarbor,ME,
USA). These mice were originally engineered by Deltagen (San
Mateo, CA, USA) and were backcrossed onto the C57BL/6 back-
ground for at least 10 generations. It should be noted that CB2
mRNAwas detected in tissues taken from CB2
2/2 animals. How-
ever, PCR combined with Sanger sequencing confirmed that this
was not the full-lengthCB2 transcript andwas therefore unlikely to
be translated into functional protein (unpublished results). Female
8–16-wk-old animals (25–30g)wereused in all experiments (unless
otherwise specified), and power calculations were carried out in
advance to determine the minimum number needed to detect an
effect size of at least 30%with P, 0.05.
Dorsal air pouch inflammation model
Femalemice were anesthetized, and air pouches were created by
dorsal subcutaneous injection of 2.5 ml sterile air on d 0 and 3.
On d 6, animalswere anesthetized andwere injectedwith 100mg
Zymosan (MilliporeSigma, Burlington, MA, USA) in 500 ml PBS.
Pouches were lavaged 2, 6, 16, or 48 h after Zymosan injection
with 3 ml PBS containing 2 mM EDTA. Blood was collected into
EDTA-coated tubes.
Flow cytometry
Dorsal air pouch exudates (300 ml) were centrifuged at 200 g for
5 min at 4°C. Cell pellets were resuspended in 50ml fluorescence-
activated cell sorting (FACS) buffer [PBS containing 2% fetal calf
serum (FCS), 25mMHEPES, and 5mMEDTA] andwere blocked
with 116 mg/ml mouse IgG (Jackson ImmunoResearch, West
Grove, PA,USA) and6.6mg/mlmouse SeroBlockFcgR (Bio-Rad)
for 15min on ice. Antibody stainingwas performed for 30min on
ice and protected from light before resuspending cells in 1%
paraformaldehyde. All samples were run on a Dako Cyan ADP
flow cytometer (BeckmanCoulter, Brea, CA,USA) and datawere
analyzed using FlowJo v.10 software (BDBiosciences). Peripheral
blood (50ml)wasmixed 1:1with blocking solution, and cellswere
stained as above. Red blood cells were subsequently lysed with 3
ml BD FACS lysing solution (BD Biosciences) for 15 min at room
temperature. Cells were washed twice with 1 ml FACS buffer
before final resuspension in 1% paraformaldehyde.
Generation of mixed bone marrow
chimeric animals
Bonemarrow cellswere isolated from female B6.SJL (CD45.1+) and
CB2
2/2animals (CD45.2+).Redbloodcell lysiswascarriedout in10
ml of ammonium-chloride-potassium lysis buffer (155mMNH4Cl;
10 mM KHCO3; 100 mM EDTA) for 5 min at room temperature
before centrifugation at 250 g for 5 min at 4°C. Cells were then
resuspended in PBS for counting, and equal numbers of CD45.1+
and CD45.2+ cells were mixed to a final concentration of 2.53 107
cells/ml. Female C57BL/6 or CB2
2/2 recipient animals were sub-
lethally irradiatedwith2dosesof 5Gyseparatedbya3-hgap.They
were then injected intravenously with 200 ml of the bone marrow
cell suspension (5 3 106 cells/mouse) and assessed after 5 wk for
bone marrow transplantation efficiency by blood flow cytometry.
Dorsal air pouches were established 1 wk later.
Cell counting
CountBright Absolute Counting Beads (50 ml; Thermo Fisher Sci-
entific,Waltham,MA,USA)were added to 300ml dorsal air pouch
exudates, and samples were analyzed by flow cytometry gating
separately on beads and cells.
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Cytokine, chemokine, and metalloproteinase
level assessment
The concentration of TNF-a, IL-6, matrix metalloproteinase 9
(MMP-9),C-Cmotif chemokine ligand(CCL)2,CCL3,CCL4,C-X-C
motif chemokine ligand (CXCL) 1, CXCL2, CXCL5, and CXCL10
was determined using DuoSet sandwich ELISA and Magnetic
LuminexScreeningAssays (R&DSystems,Minneapolis,MN,USA)
followingthemanufacturer’sguidelines.Opticaldensityabsorbance
wasmeasuredat450nmwithcorrectionat570nmusingaPherastar
plate reader (BMG Labtech, Offenburg, Germany). Luminescence
wasmeasuredwith aBio-Plex 200System (Bio-Rad). Theamountof
each analyte was interpolated from the protein standard curve and
multiplied with the appropriate dilution factor.
Culture and stimulation of dorsal air
pouch fibroblasts
Dorsal air pouches were injected with 3 ml prewarmed TrypLE
Express (Thermo Fisher Scientific) for 15min at 37°C, and exudates
werecollectedinto6mlDMEMcontaining10%FCS.Cellswere then
passed through a 45-mm cell strainer and centrifuged at 200 g for
5 min at 4°C. They were then resuspended in 3 ml DMEM con-
taining 10% FCS and seeded into 6-well plates. Medium was
replaced every 2 d until cells reached 90% confluency. Fibroblasts
were detached from plastic following a 5-min incubation with
TrypLE Express at 37°C and resuspended in DMEM containing
10%FCS for cell countingusing trypanblue exclusion.Cells (23106
cells/ml) were plated in 12-well plates overnight at 37°C/5% CO2
for stimulation with vehicle or Zymosan (10 mg/ml) for 6 h.
RNA extraction and cDNA synthesis
RNA extraction was conducted using the RNeasy Mini Kit
(Qiagen).RNAconcentrationandqualityweredeterminedusing
a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Sci-
entific). cDNA was synthesized from purified RNA (500 ng) us-
ing theQuantiTect Reverse Transcription Kit (Qiagen) following
the manufacturer’s protocol.
qPCR
Actin g1 (Actg1), cannabinoid receptor 2 (Cnr2), vimentin (Vim),
Tlr2 (Toll-like receptor 2), C-type lectindomain family 7,member
a (Clec7a) (Dectin-1), C-C chemokine receptor 7 (Ccr7),Ccl22, and
Cxcl10 expression was determined in qPCR experiments. cDNA
(50 ng) was used as a template, and master mix reactions con-
tained 23SYBRSelect PCRmastermix (ThermoFisher Scientific),
primers (500 nM) (Table 1), and nuclease-free water. The thermal
profile used consisted of a denaturation step at 95°C for 5 min,
40 cycles of 95°C for 30 s, 60°C for 20 s, 72°C for 30 s, and a
final elongation step of 72°C for 5 min. Samples were analyzed
using a StepOnePlus Thermal Cycler (Thermo Fisher Scientific),
setting the cycle threshold in the linear phase of the amplification
plots.
Neutrophil transcriptome analysis
Wild-type (WT) and CB2
2/2 neutrophils harvested from dorsal
air pouches at 6 h post–Zymosan challenge were negatively se-
lected (Miltenyi Biotec, Bergisch Gladbach, Germany), and
transcriptome analysis was carried out using the nCounter
Mouse Inflammation V2 panel (NanoString Technologies, Seat-
tle, WA, USA) consisting of 248 genes and 14 positive/negative
probes.Cells (53 106/ml)were lysedandprocessed according to
the manufacturer’s guidelines. Data were analyzed in R (v.3.3.1)
using the NanoStringDiff package (v.1.2.0) (27) and its default
settings. Briefly, raw nCounter data were converted into a
NanoStringSet object including 6 positive controls, 8 negative
controls, and 5 housekeeping genes (Cltc,Gapdh,Gusb, Pgk1, and
Tubb5) per sample. The data were normalized and analyzed for
differentially expressed genes according to NanoStringDiff in-
structions following a 2-group comparison approach.
Murine neutrophil static adhesion assay
Purified bone marrow WT and CB2
2/2 neutrophils (105 cells)
were treated with vehicle, complement component 5a (C5a) (10
nM; R&D Systems), or N-formylmethionine-leucyl-phenylala-
nine (fMLP) (20 nM;R&DSystems) for 15min at 37°C andplated
in a 96-well plate precoated with 12.5 mg/ml ICAM-1–Fc [1 h at
37°C, washed in PBS and blocked in PBS with 1% bovine serum
albumin (BSA) for 45min; R&D Systems] for another incubation
of 15 min at 37°C. Cells were washed in PBS, and their numbers
were determined after a 10-min incubation with PrestoBlue
(Thermo Fisher Scientific) at 540 nm excitation and 590 nm
emission using a Pherastar plate reader.
Human neutrophil transendothelial
migration assay
Primary human dermal blood endothelial cells (HDBECs) were
purchased from PromoCell and cultured in the manufacturer’s
recommended endothelial cell growth medium MV (PromoCell,
Heidelberg, Germany). HDBECswere seeded onto 24-well tissue
culture plates after 4 passages at a seeding density yielding con-
fluent monolayers. Prior to the adhesion assay, HDBEC mono-
layers were washed in endothelial cell growth medium MV
warmed to 37°C and cytokine simulated using TNF-a (100U/ml;
MilliporeSigma) for 4 h at 37°C. Neutrophils were isolated
from whole human blood as previously described in Cooper
et al. (28).Neutrophilswere treatedwithvehicle (1%DMSO),1mM
JWH133 {aCB2-selectiveagonist; (6aR,10aR)-3-(1,1-dimethylbutyl)-
6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran}, or
1 mM JWH133 and 1 mMSR144528 {a CB2-selective antagonist;
5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-
[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-
carboxamide} for 15 min prior to use.
Prior to beginning the assay,HDBECmonolayerswerewashed
with 37°C medium 199 (Thermo Fisher Scientific) supplemented
TABLE 1. Primer pair sequences used in this study
Sequence, 59→39
Gene Sense Antisense
Mm_Cnr2 GGTCCTCTCAGCATTGATTTC GCCCAGTAGGTAGTCGTTAG
Mm_Vim TGAAGGAAGAGATGGCTCGT GGAAGAAAAGGTTGGCAGAG
Mm_Tlr2 CTCCCACTTCAGGCTCTTTG GCCACTCCAGGTAGGTCTTG
Mm_Clec7a CAGGGAGAAATCCAGAGGAG TAGGAAGGCAAGGCTGAGAA
Mm_Actg1 CCAACAGCAGACTTCCAGGATT CTGGCAAGAAGGAGTGGTAACTG
Actg1, actin g1.
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with 0.15% w/v BSA (MilliporeSigma) to remove any residual
cytokines. Treated neutrophils (0.15 3 106) were cocultured with
cytokine-stimulatedHDBECmonolayersat37°Cfor6minand30s.
To remove any cells adherent by electrostatic interactions, the
monolayers were washed twice with 37°C medium 199 supple-
mented with 0.15% w/v BSA. HDBEC monolayers and adherent
neutrophilswere then fixed in 2%glutaraldehyde (MilliporeSigma)
for 15 min and washed twice in PBS. The extent of neutrophil ad-
hesion and transmigration was imaged using phase-contrast mi-
croscopywith an inverted bright-fieldmicroscope (IX71;Olympus,
Tokyo, Japan)at332magnification.Atotalof5 imagesof5different
viewswere taken perwell and processed offline using Image Pro 7
software (Media Cybernetics, Rockville, MD, USA). Neutrophils
weremanually tagged as being surface adherent (phase bright and
rounded) or as having transmigrated (phase dark with altered
morphology). Total neutrophil adhesion and mean percentage
transmigration were calculated for each well.
Data and statistical analysis
All data are reported as the mean + or 6 SEM of independent
experiments and were analyzed using Prism v.7 (GraphPad
Software, La Jolla, CA, USA). For 2-group comparisons, a Stu-
dent’s t testwas applied,whereas formultiple comparisonswith
1 or 2 variables, a 1-way ANOVA with Dunnett’s multiple
comparisons correction and a 2-way ANOVA with Sidak’s
multiple comparisons correction were applied, respectively.
Results were considered statistically significant when P, 0.05.
RESULTS
Characterization of the leukocyte recruitment
pattern in CB2
2/2 mice
To examine how CB2 regulates immune cell trafficking in
vivo, we decided to use the dorsal air pouch model of in-
flammation, as it offers the advantage of an accessible
administration site for inflammatory stimuli and simple
quantitative collection of the inflammatory exudate. Zy-
mosanhas been used to elicit an inflammatory response in
several animalmodels, including the dorsal air pouch (29,
30) and was therefore chosen as the inflammatory insult.
We began by analyzing the immune cell composition
of dorsal air pouches from WT and CB2
2/2 female mice
under baseline conditions and upon challenge with Zy-
mosan (100 mg) across a range of time points. Leukocyte
numbers (total CD45+ cells) in the pouches were similar
between WT and CB2
2/2 mice under basal conditions
(Supplemental Fig. S1A, E, I). In addition, we found that
neutrophils [CD45+, CD1152, Ly-6G+, and Ly-6Clo; Sup-
plemental Fig. S1C, G] as well as the Ly-6Clo and Ly-6Chi
monocyte (CD45+, CD115+; Supplemental Fig. S1D, H)
populations were present in the pouches of both WT and
CB2
2/2 animals, and their numbers were comparable
between the 2 genotypes (Supplemental Fig. S1I–L).
Zymosaninjection intopouchesofWTanimals led toan
increase in the numbers of total CD45+ cells, which
reachedapeakat16handreturned tobaselineat 48h.CB2-
deficient animals demonstrated a significantly higher
(P, 0.01) 4-fold influx of totalCD45+ cells andneutrophils
at 6 and 16 h (Fig. 1A, B). Analysis of CD45+ cell compo-
sition revealed that neutrophils were the dominant pop-
ulation, making up 60–70% and 75–80% of all leukocytes
at 6 and 16 h, respectively.
In contrast, Ly-6Clo monocyte numbers remained rel-
atively constant in both genotypes until 48 h, when a
significantly higher (P , 0.01) influx was seen in mice
lacking CB2 (Fig. 1C). Conversely, the number of Ly-6C
hi
monocytes rose sharply at 2 h and almost returned to
baseline at 6 h in bothWT andCB2-deficient animals (Fig.
1D). There was a significantly (P , 0.001) more potent
secondary mobilization of Ly-6Chi monocytes in CB2
2/2
animals at 16 h compared with WT controls (Fig. 1D).
Taken together, our data show that genetic deletion of
CB2 results inaugmentedacute recruitmentofCD45
+ cells
and, particularly, neutrophils and Ly-6Chi monocytes to
the site of inflammation in the dorsal air pouchmodel. Of
note, the kinetics of Ly-6Chi monocyte recruitment differ
from those of neutrophils in that their trafficking is exac-
erbated during a second wave of leukocyte recruitment.
Increased leukocyte recruitment to the air
pouch in CB2-deficient mice is not due to
increased blood leukocyte numbers
To assess whether the observed increased neutrophil and
Ly-6Chi monocyte recruitment to the pouches of CB2
2/2
animals was due to a parallel increase in their numbers in
the blood,we next examined the immune cell composition
in the circulation of WT and CB2
2/2 mice during the in-
flammatory challenge. Zymosan administration caused a
rapid increase in the number of total CD45+ cells, neutro-
phils, and Ly-6Chimonocytes in the blood of bothWT and
CB2
2/2 animals, which returned to baseline at 16 h (Fig.
1E, F, and H). Interestingly, the numbers of Ly-6Chi
monocytes exhibited a secondary peak at the 48-h time
point (Fig. 1H). The numbers of Ly-6Clo monocytes
remained stable until 48h,whena 3-fold increasewas seen
in both genotypes (Fig. 1G). None of the dynamic changes
in cell numbers in the air pouch was associated with sta-
tistically meaningful differences in leukocyte numbers in
the blood of WT and CB2
2/2 animals at any time point
analyzed. Collectively, our findings show that the in-
creased recruitment of neutrophils andLy-6Chimonocytes
into the air pouch of CB2
2/2 animals cannot be attributed
to changes in leukocyte numbers in the blood.
Elevated levels of MMP-9 and monocyte-
recruiting chemokines are observed in
pouch exudates of CB2
2/2 mice
A plausible mechanistic explanation for the augmented
acute recruitment of innate immune cells to the pouch
of CB2
2/2 mice would be elevated production of local
chemokines. We therefore measured the inflammatory
mediator levels in thepouches ofWTandCB2
2/2animals
at 2 and 6 h following the Zymosan challenge because
these time points preceded the increased acute neutrophil
and Ly-6Chi influx seen in CB2
2/2 mice. We found no
statistically significant difference in the levels of IL-6,
MMP-9, CCL2, CCL4, CXCL1, -L2, -L5, or -L10 at 2 h (Fig.
2), whereas the levels of IL-6, CXCL1, -L2, and -L5 de-
creased similarly at 6 h in both genotypes. Nevertheless,
the levels of MMP-9, CCL2, CCL4, and CXCL10 (Fig.
2B–D, H) were significantly higher (P , 0.05) in the
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exudates of CB2
2/2 mice, implying that the increased
neutrophil and Ly-6Chi monocyte influx in CB2
2/2 ani-
mals may be due in part to elevated local metal-
loproteinase and chemokine secretion.
Male CB2
2/2 animals also display an enhanced
inflammatory phenotype
To rule out the possibility that our observations were
gender-specific, we compared leukocyte recruitment and
inflammatorymediator production in thepouches ofmale
WT and CB2
2/2 mice at 6 h upon Zymosan administra-
tion. Similar to our data with female animals, neutrophils
constituted the dominant leukocyte population at 6 h
(Supplemental Fig. S2A,C) and, togetherwith total CD45+
cells, were significantly greater in number (P, 0.05) in the
pouches of CB2
2/2male mice (Supplemental Fig. S2E, F).
Of note, the effect size observed in male animals was
smaller than that of females (Fig. 1A,B in comparisonwith
Supplemental Fig. S2E, F). Lastly, Ly-6Clo and Ly-6Chi
monocytes were also present in the pouches of male mice
(Supplemental Fig. S2B, D), but we did not detect any
differences in their absolute numbers between the geno-
types at 6 h (Supplemental Fig. S2G, H).
Analysis of the levels of inflammatorymediators in the
pouch exudates of CB2
2/2 male mice at 6 h showed that
IL-6 and CCL2 were significantly higher (P , 0.05)
(Supplemental Fig. S2I, J), whereas the levels of CXCL1
were comparable between the 2 genotypes (Supplemental
Fig. S2K). Altogether, these data demonstrate that the in-
crease in neutrophil numbers at the peak time point of 6 h
was not gender-dependent but reflected the altered bi-
ology during CB2 deficiency. However, in order to search
for the potential mechanisms underlying enhanced neu-
trophil recruitment to the dorsal air pouch in CB2
2/2 an-
imals, we chose to focus on female mice because of the
larger difference in neutrophil recruitment between WT
and transgenic animals.
Cultured cells from the pouch lining of WT and
CB2
2/2 mice secrete comparable levels of
inflammatory mediators
To identify the cell types responsible for the increased in-
flammatory mediator secretion observed in CB2
2/2mice,
we isolated the mesothelium lining of WT and CB2
2/2
pouches and tested the response to in vitro Zymosan
stimulation. The presence of Vim expression in WT and
CB2
2/2 pouch lining cells confirmed their fibroblast-like
phenotype (Fig. 3A). Under basal conditions, both WT
and CB2
2/2 pouch fibroblasts expressed Cnr2 (residual
Cnr2 expressionwasdetectable in fibroblasts fromCB2
2/2
mice) and low levels of the Zymosan receptor Tlr2
and Dectin-1 (Clec7a) transcripts (Fig. 3B). Following
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Figure 1. CB2 deﬁciency results in an exaggerated acute inﬂammatory response in the dorsal air pouch inﬂammation model.
Dorsal air pouches of 8–10-wk-old female WT and CB2
2/2 mice were injected with 100 mg Zymosan and lavaged at the indicated
time points. A–D) Absolute numbers of total CD45+ cells (A), neutrophils (CD45+, Cd1152, Ly-6G+, Ly-6Clo) (B), Ly-6Clo (C), and
Ly-6Chi monocytes (CD45+, CD115+) (D) were determined by ﬂow cytometry. E–H) Blood was also withdrawn from the same
animals and numbers of total CD45+ cells (E), neutrophils (F), Ly-6Clo (G), and Ly-6Chi (H) monocytes per milliliter of blood
were determined by ﬂow cytometry. Data are means 6 SEM (n = 5–11 animals/group). Statistical analysis was conducted by 2-way
ANOVA with Sidak’s multiple comparisons correction. **P , 0.01, ***P , 0.001.
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stimulation with Zymosan for 6 h, the fibroblasts from
both genotypes down-regulated Cnr2 expression signifi-
cantly (P, 0.001) and increased (P, 0.01) that of Tlr2 to a
similar level with that seen in Bio-gel–elicited macro-
phages (Fig. 3C). In contrast, Clec7a expression levels
remained negligible in pouch lining cells from both ge-
notypes, even after Zymosan stimulation (Fig. 3D).
Finally, Zymosan stimulation of bothWT and CB2
2/2
pouch fibroblasts induced a significant increase (P ,
0.001) in the production of IL-6, CCL2, CXCL1, and
CXCL5, although no statistically significant difference
was observed in the levels of any of these mediators be-
tween genotypes (Fig. 3E–H). Our results demonstrate
that the pouch lining contributes to the inflammatory re-
sponse to Zymosan challenge, but the absence of endog-
enous CB2
2/2 does not enhance the production of
common neutrophil and Ly-6Chi monocyte–recruiting
inflammatorymediators. It is therefore unlikely that these
fibroblast-like cells are responsible for the increased in-
nate immune cell recruitment seen in CB2
2/2mice.
Absence of CB2 on neutrophils results in
enhanced recruitment to local site
of inflammation
To test the hypothesis that the specific absence of CB2 on
neutrophils may directly alter their migratory behavior,
we generated bone marrow chimeric animals following
the scheme detailed in Supplemental Fig. S3A. To confirm
success of the bone marrow repopulation, tail blood was
withdrawn from each animal 5 wk later to assess the rel-
ative proportion of CD45.1 to CD45.2 cells (Supplemental
Fig. S3B, C). Quantification of cell numbers clearly dem-
onstrated that therewasnodifference in theabsolute levels
of CD45.1 and CD45.2 leukocytes in the blood of bothWT
and CB2
2/2 recipient animals (Supplemental Fig. S3D).
Assessment of leukocyte recruitment to the pouches of
WT and CB2
2/2 recipient chimeric mice 6 h after Zymosan
injection revealed no difference in the number of recruited
totalCD45+cells (Fig. 4A) between the2genotypes,whereas
neutrophils were themost prevalent immune cell type (Fig.
4B, E). Consistent with a neutrophil-specific effect of CB2
deficiencyduring the acute phase of inflammation, our data
revealedthat thispopulationwasmadeupofproportionally
moreCD45.2+ thanCD45.1+ cells, regardless of the recipient
genotype (Fig. 4C, F). Quantification of CD45.1+ and
CD45.2+ neutrophils in bothWTandCB2
2/2 recipientmice
conclusively demonstrated that CD45.2+ CB2
2/2 neutro-
phils migrated more readily into the pouch than their
CD45.1+ WT counterparts at 6 h (Fig. 4H). We observed a
minor Ly-6Chi monocyte population in both recipient ge-
notypes (Fig. 4B, E) that consisted of equal proportions of
CD45.1+andCD45.2+cells (Fig. 4D,G).Quantificationofcell
numbers showed that this immune cell type infiltrated the
dorsal air pouch of bothWT and CB2
2/2 recipient animals
independently of their CB2 expression profile (Fig. 4I).
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Figure 2. MMP-9 and CC chemokine secretion is higher in the dorsal air pouch exudates of CB2
2/2 mice. Dorsal air pouches of
8–10-wk-old female WT and CB2
2/2 mice were injected with 100 mg Zymosan and lavaged 2 and 6 h later for inﬂammatory
mediator level measurement. IL-6 (A), MMP-9 (B), CCL2 (C), CCL4 (D), CXCL1 (E), CXCL2 (F), CXCL5 (G), and CXCL10
(H) levels were determined by ELISA or Luminex assays. Data are means 6 SEM (n = 6–14 animals/group). Statistical analysis was
conducted by 2-way ANOVA with Sidak’s multiple comparisons correction. *P , 0.05.
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Finally, to exclude the existence of disproportionate
numbersofCD45.2+neutrophils in thecirculationofWTand
CB2
2/2 recipient animals as an explanation for their in-
creasednumbers in the pouches,we quantified the numbers
ofCD45.1+ andCD45.2+ neutrophils in blood from the same
animals and found that there was no significant difference
(Fig. 4J). The samewas also true for Ly-6Chimonocytes (Fig.
4K). Taken together, our data rule out the explanation that
the increasednumbersofCD45.2+CB2
2/2neutrophils in the
pouches of bonemarrow recipientmice is due to differences
in theirnumbers in thebloodstreamandclearlydemonstrate
that a lack of CB2 on the neutrophils themselves is re-
sponsible for their increased trafficking into the pouches of
CB2
2/2 animals during acute inflammation.
CB2
2/2 neutrophils overexpress
promigration transcripts
In our experiments, neutrophilswere the predominant cell
type among leukocytes in the acute phase of the dorsal air
pouch model. Therefore, we undertook a transcriptional
analysis of neutrophils present in theair pouch exudates of
WT and CB2
2/2 mice. We purified neutrophils from
pouches ofWT andCB2
2/2 animals at 6 h post–Zymosan
challenge and performed a NanoString transcriptomic
analysis. Comparison of the expression levels of the 243
genes present in the nCounterMouse Inflammation panel
between WT and CB2
2/2 neutrophils identified 36 genes
thatweredifferentially expressedbetween the2genotypes
(Fig. 5A). The expressionof 24geneswas significantly (P,
0.05) up-regulated (Fig. 5B), whereas 6 genes were signif-
icantly (P , 0.05) down-regulated (Fig. 5C). We addi-
tionally applied a 2-fold change cutoff to focus on
differentially expressed genes with a larger effect size.
Genes significantly overexpressed in CB2
2/2 neutrophils
belonged to several ontology categories, including che-
mokines and chemokine receptors (Ccr7, Ccl22, Cxcl10,
Cxcl3, and C-X-C motif chemokine receptor 1), cytokines
(Il5, Il23a, Il1a, and Il1b), T-cell costimulatory molecules
(Cd40, histocompatibility 2, class II antigen Eb, andCd86),
inflammasome activation [NLR family, pyrin domain
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Figure 3. CB2 deletion in dorsal air pouch ﬁbroblasts has no effect on inﬂammatory mediator production in response to
Zymosan. A–D) Dorsal air pouch lining endothelial cells from WT and CB2
2/2 female mice (8–10 wk old) were harvested and
stimulated with 10 mg/ml Zymosan or vehicle for 6 h. Vim (A), Cnr2 (B), Tlr2 (C), and Clec7a (D) gene expression was
determined by qPCR. E–H) Gene expression from Bio-gel macrophage samples is shown for comparison. IL-6 (E), CCL2 (F),
CXCL1 (G), and CXCL5 (H) levels from culture supernatants were determined by ELISA. ND, not detected; NS, not signiﬁcant.
Data are means + SEM (n = 5–7 biologic replicates). Statistical analysis was conducted by 2-way ANOVA with Sidak’s multiple
comparisons correction. *P , 0.05, **P 5 0.01, ***P , 0.001.
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containing 3 (Nlrp3)], complement components (comple-
ment component 1q B chain), prostaglandin pathways
(post-transcriptional gene silencing2 andprostaglandin I2
receptor), and signaling pathways (PKC-b and TNF-a–
induced protein 3) (Fig. 5B). On the other hand, genes
significantly down-regulated in CB2
2/2 neutrophils were
related to pathogen recognition receptors (Tlr9), lectins
(chitinase 3-like protein 3), and nitrite production (Nos2)
(Fig. 5C).
To validate these findings, we assessed the expression
levels of representative genes related to neutrophil mi-
gration with qPCR. Expression level differences of Ccr7
(Fig. 5D),Ccl22 (Fig. 5E), andCxcl10 (Fig. 5F) betweenWT
and CB2
2/2 neutrophils corroborated the NanoString
data. Our data demonstrate that neutrophils, which lack
CB2, overexpress genes associated with chemotaxis and
inflammatory cell recruitment during the acute in-
flammatory response induced by Zymosan stimulation.
Enhanced CB2
2/2 neutrophil adhesion
to ICAM-1
We next wanted to explore whether neutrophils lacking
CB2 have altered adhesive properties, potentially pro-
viding a mechanistic explanation for the enhanced re-
cruitment of CB2
2/2 neutrophils in the air pouch model.
Therefore, we performed an in vitro static adhesion assay.
Briefly, purified neutrophils from the bonemarrow ofWT
and CB2
2/2mice were stimulated with vehicle, the com-
plement peptide C5a, or the bacterial component fMLP
and then incubated in ICAM-1–treated culture plates.
Following extensive washing, adhered neutrophils were
quantified. Although vehicle-stimulated neutrophils from
both genotypes showed no variation in adherence to
ICAM-1–treated plates, CB2
2/2 neutrophil numberswere
significantly higher when pretreated with C5a (P , 0.01)
and fMLP (P , 0.05) than their WT counterparts (Fig. 6).
Taken together, our in vitro findings support a model in
which the absence of CB2 signaling increases the adhesion
of neutrophils to endothelial cell integrins, which facili-
tates their transmigration to sites of inflammation.
Activation of CB2 in human neutrophils blocks
endothelial transmigration
Because a lack of CB2 promotes the adhesion of neu-
trophils to ICAM-1, and CB2
2/2 mice have increased
neutrophil recruitment during acute inflammation, we
reasoned that pharmacological activation of CB2 should
result in an opposing effect and would therefore block
neutrophil adhesion to TNF-a–activated endothelial cells
and their subsequent transmigration. To test this hy-
pothesis, we examined human neutrophil adhesion and
transmigration on a TNF-a–activated endothelial mono-
layer following CB2 agonist treatment in vitro. When
treated with vehicle alone (1% DMSO), both adhered
(phase-bright cells; Fig. 7A) and transmigrated (phase-
dark cells; Fig. 7A) neutrophils could be clearly seen.
Treatment with the CB2-selective agonist JWH133 (1 mM)
caused a significant reduction in the total number of ad-
hered and transmigrated neutrophils (representative im-
age, Fig. 7B, D, E). The reduction in both neutrophil
adhesion and transmigration seen with JWH133 treat-
ment was fully reversed by coincubation with the CB2-
selective antagonist SR144528 (1 mM; representative im-
age, Fig. 7C–E).We believe that taken together, these data
demonstrate that the specific activation of CB2 in human
neutrophils is sufficient to block their endothelial adhe-
sion and transmigration.
DISCUSSION
In this study, we have demonstrated for the first time that
global CB2 deficiency results in enhanced neutrophil
and Ly-6Chi monocyte recruitment in the dorsal air
pouch model of inflammation, and our main findings are
summarized in Fig. 8. The neutrophil mixed bone mar-
row chimera experiments unambiguously demonstrate
cell-autonomous effects of CB2 genetic deletion on mobi-
lized neutrophils, which exhibit an enhanced migratory
transcriptional profile. Our novel findings with murine
neutrophils are supported by experiments in which
pharmacological activation of CB2 receptors on human
polymorphonuclear neutrophils (PMNs) blocks endothe-
lial transmigration in vitro. Previous studies have docu-
mented anti-inflammatory effects of CB2 agonists in a
range of murine models of inflammation at single time
points or single doses (15, 18, 22, 31–36). By using multi-
color flow cytometry to accurately identify immune cell
subsets (37, 38) and by performing a full kinetic analysis,
rather than the single endpoint approaches, we were able
to fully examine the role of CB2 throughout the acute
inflammatory response. Our detailed analysis of acute
inflammation in global CB2-knockout animals is consis-
tent with cannabinoid signaling providing a tonic anti-
inflammatory arm in the host response to injury and
infection (10, 39, 40).
Importantly, the significant increase of neutrophil
numbers in the pouches of CB2
2/2 animals cannot be at-
tributed to differences in their numbers in the pouch or
blood under basal conditions. Hence, increased pouch
neutrophil numbers must be a result of augmented mo-
bilization to the injury site. Previous in vitro experiments
lavaged 6 h after 100 mg Zymosan injection, and absolute numbers of total CD45+ cells (A) as well as representative dot plots of
CD45+CD11b+ cells (B, E), neutrophils (C, F), and monocytes (D, G) were determined by ﬂow cytometry from WT and CB2
2/2
recipient animals, respectively. H–K) Absolute numbers of CD45.1+WT and CD45.2+CB2
2/2 neutrophils (H) and Ly-6Chi
monocytes (I) recruited to the dorsal air pouches of WT and CB2
2/2 recipient mice. Blood was also withdrawn from the same
animals, and numbers of CD45.1+WT and CD45.2+CB2
2/2 neutrophils (J ) and Ly-6Chi monocytes (K) per milliliter of blood
were determined by ﬂow cytometry. NS, not signiﬁcant. Data are means + SEM (n = 9–11 animals/group). Statistical analysis was
conducted by 2-way ANOVA with Sidak’s multiple comparisons correction. **P , 0.01, ***P , 0.001.
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Figure 5. CB2
2/2 neutrophils from dorsal air pouches display higher expression of migration-related molecules. Dorsal air pouches of
8–10-wk-old female WT and CB2
2/2 mice were injected with 100 mg Zymosan and lavaged 6 h later. Recruited neutrophils were
puriﬁed with negative selection, and their transcriptome was proﬁled with the nCounter Gene Expression Kit. A) 36 genes were
differentially expressed (DE) in CB2
2/2 neutrophils. Spearman correlation and average linkage were chosen as the clustering
parameters in the heatmap. Each row represents 1 gene, and each column represents neutrophils isolated from an independent WT
or CB2
2/2 animal. B–F) List of at least 2-fold up-regulated (B) and down-regulated (C) DE genes in CB2
2/2 neutrophils. Ccr7 (D),
Ccl22 (E), and Cxcl10 (F) gene expression was validated by qPCR. Data are means + SEM (n = 5 independent neutrophil puriﬁcations/
genotype). Statistical analysis was conducted by a 1-tailed Student’s t test with Welsh’s correction. *P, 0.05, **P, 0.01, ***P, 0.001,
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have demonstrated that CB2 activation may suppress
neutrophil and monocyte chemotaxis (41–43); however,
additional lines of evidence in dendritic cell biology have
demonstrated that CB2 does not inhibit chemotaxis per se,
but rather down-regulates MMP-9 levels to reduce cell
invasiveness (44). Our findings support the idea that CB2
regulates neutrophil invasion, potentially via the metal-
loproteinase MMP-9, because we found that a lack of CB2
in murine neutrophils increased their adhesion to ICAM,
the specific pharmacological activation of human neutro-
phils blocked their endothelial transmigration, andCB2
2/2
animals had significantly higher levels of MMP-9 in the
pouch exudate 6 h after Zymosan challenge. Indeed, our
laboratory recently demonstrated that neutrophil in-
filtration to the spleen is regulated by CB2 via MMP-9 re-
duction in a low dose endotoxemia model (45), and others
have found higher MMP-9 levels in atherosclerotic lesions
fromCB2
2/2animals (46). Because neutrophils are amajor
source of MMP-9 (47), CB2
2/2 neutrophils may express
higher levels of MMP-9, which could enhance their in-
vasive capacity, resulting in increased pouch neutrophil
recruitment.However, it is possible that the increased levels
of MMP-9 may be reflective of the increased numbers of
neutrophils seen in CB2
2/2 animals, and that the mecha-
nism underlying enhanced recruitment lies elsewhere.
It has been proposed that CB2 mediates its anti-
migratory effects on leukocytes indirectly via the endo-
thelium (48, 49). However, our work with mixed bone
marrow chimeras and the ex vivo culture of pouch lining
cells ruled out the involvement of stromal cells in the in
vivo phenotype of CB2-deficient animals, and our tran-
scriptomic analysis and the adhesion assay outlined in Fig.
6 identified a dysregulated phenotype of CB2
2/2 neutro-
phils harvested directly from the site of inflammation. The
up-regulated expression levels of cytokines, chemokines,
chemokine receptors, complement receptors, and activa-
tion markers in CB2
2/2 neutrophils further support the
idea that unregulated neutrophil activation could lead
to increased PMN recruitment via an autocrine feedback
loop (50).
The second main finding of the current study is the
effect of CB2 deficiency on Ly-6C
hi monocyte recruitment
to the pouches. It is noteworthy that Ly-6Chi monocyte
trafficking follows a biphasic pattern in both genotypes
and is exacerbated in CB2
2/2mice in the second wave of
inflammation. In fact,Newson et al. (51) recently proposed
that the second wave of monocytes aims to induce regu-
latory T-cell differentiation and resolution of the un-
dergoing local inflammation. In our study, this would
mean that CB2 deficiency accelerates the resolution of in-
flammation in the pouch. Support for this hypothesis is
provided by the fact that inCB2
2/2mice, the rate atwhich
inflammatory cell numbers returned to baseline following
their peakwas greater than that ofWTmice. Additionally,
there were significantly more pouch Ly-6Clo monocytes
in CB2
2/2 animals 48 h after the Zymosan challenge,
and these cells havebeen suggested to have a protective or
anti-inflammatory role and to give rise to alternatively
activated macrophages that aid tissue repair and the res-
olution of inflammation (52–54). However, further exper-
iments will clearly be needed to confirm this hypothesis.
An obvious explanation for the increased Ly-6Chi
monocyte recruitment observed in CB2
2/2 animals is the
elevated CCL2, CCL4, and CXCL10 secretion in the exu-
dates. It is not clear from our experiments whether these
mediators are released fromstromal cells at equal levels by
the 2 genotypes or whether the accumulation of neutro-
phils in CB2
2/2mice is the main reason for their elevated
levels in the air pouch. In keeping with the latter scenario,
we found thatCB2
2/2neutrophils overexpressCxcl10, the
up-regulation of which is critical for T helper cell differ-
entiation and trafficking (55).
An important implication from this study is that
endocannabinoids, signaling via CB2, act to reduce neu-
trophil recruitment during acute inflammation. Indeed,
the endocannabinoids 2-arachidonoylglycerol (2-AG) and
anandamide have been previously demonstrated to in-
hibit fMLP-induced human neutrophil chemotaxis and T-
cell migration toward CXCL12 (56, 57). However, and
seemingly at odds with this inhibitory function, multiple
studies have found that 2-AG on its own can stimulate the
directed migration of a range of immune cell types (58).
Nevertheless,we recentlydemonstrated that 2-AGdidnot
act as a chemoattractant for primarymurinemacrophages
(26), andOka et al. (59) foundthat 2-AGwasunable to elicit
chemotaxis of human neutrophils, thereby strongly sug-
gesting that endocannabinoid-mediated immune cell mi-
gration is cell type–specific and likely not of relevance to
neutrophils. Instead, we believe the findings presented
here using CB2
2/2 animals fit with the hypothesis that
endocannabinoids acting viaCB2, lead to a reduction in the
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Figure 6. CB2
2/2 neutrophils from bone marrow adhere more
to ICAM-1 upon stimulation with complement and bacterial
products. Bone marrows of 8–10-wk-old female WT and CB2
2/2
mice were harvested, and neutrophils were puriﬁed with negative
selection. Cells were incubated with vehicle, 10 nM C5a, or
20 nM fMLP for 15 min at 37°C and were then transferred to
ICAM-1–precoated 96-well plates to adhere for another 15 min.
Adhesion quantiﬁcation was carried out with the PrestoBlue
dye. Data are means + SEM (n = 4 independent neutrophil
puriﬁcations/genotype). Statistical analysis was conducted by
2-way ANOVA with Sidak’s multiple comparisons correction.
*P , 0.05, **P , 0.01.
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inflammatory and migratory behavior of neutrophils,
which limits their recruitment to sites of inflammation.
Collectively, this is in linewith the vast array of studies
showing that the activation of CB2 by its endogenous li-
gands results in anti-inflammatory effects (60, 61). How-
ever, the role CB2 plays during an inflammatory response
is not so clear-cut because there is a growing body of
evidence that demonstrates a proinflammatory role for
the endocannabinoids both in vitro and in vivo (61). Ad-
ditionally, it has been previously shown that 2-AG can
actually enhance immune cell adhesion, either by acting
directly on the immune cells, per se, or by up-regulating
adhesion molecules on endothelial cells (62, 63). With
regard to this latter discrepancy, we believe that cell
type differences are likely responsible because neither of
the aforementioned studies examined neutrophils and
we have already ruled out an endothelial component to
our results, as previously detailed. Why some in vivo
studies demonstrate that endocannabinoids have proin-
flammatory properties remains more difficult to answer.
In these situations, context is key because each in-
flammatory model used has its own unique pathophysi-
ology, local context, and immunecell involvement,within
which the types and levels of the endocannabinoids and
receptors present may vary dramatically (64). Together,
these factors likely determine how the endocannabinoid
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Figure 7. The CB2 agonist JWH133 blocks the endothelial adhesion and transmigration of human neutrophils in a CB2-
dependent manner. A–C) Representative images of human PMNs adhered to (yellow circle) or transmigrated through (red
circle) TNF-a–activated endothelial cells that were preincubated with either 1% DMSO (A), JWH133 (1 mM) (B), or JWH133 +
SR144528 (both 1 mM) (C). D, E) Total adhesion (D) and transmigration (E) were quantiﬁed. Data are means + SEM (n = 6
independent human donors). Statistical analysis was conducted by 1-way ANOVA with Holm-Sidak’s multiple comparisons
correction. *P , 0.05, **P , 0.01.
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Figure 8. Graphical summary of the main
ﬁndings presented in this study. Dorsal
air pouches were established in WT and
CB2
2/2 mice by the dorsal subcutaneous
injection of air and were subsequently
injected with 100 mg Zymosan. Animals
genetically deleted for CB2 have an
exaggerated acute inﬂammatory response
because they have signiﬁcantly more
neutrophils, Ly-6Chi inﬂammatory mono-
cytes, and proinﬂammatory mediators
present in the pouch after Zymosan challenge in comparison with WT animals. Interestingly, it is the lack of CB2 on the
neutrophils themselves that makes them more likely to trafﬁc into the dorsal air pouch, likely due to CB2
2/2 neutrophils having
an enhanced migratory transcriptional proﬁle and increased endothelial adhesion and transmigration.
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system as a whole impacts the inflammatory response,
but clearly further work is needed to fully unravel the
complexities of this lipid signaling system in vivo.
Our working hypothesis is that lack of CB2 on neu-
trophils during inflammation releases the brake in
their migratory capacity. CB2 deficiency therefore grants
these cells increased invasive capacity and activation
potential, which can be detrimental via continued re-
cruitment of leukocytes to the inflamed site. In summary,
this study supports the notion that pharmacological ac-
tivation of CB2 could be a suitable therapeutic avenue for
the treatment of human inflammatory diseases because
of its inhibitory effects on neutrophil recruitment during
an acute inflammatory response.
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